» Articles » PMID: 38139125

Neuroprotection and Mechanism of Gas-miR36-5p from in an Alzheimer's Disease Model by Regulating Glycogen Synthase Kinase-3β

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Dec 23
PMID 38139125
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is currently the most common neurodegenerative disease. Glycogen synthase kinase 3β (GSK-3β) is a pivotal factor in AD pathogenesis. Recent research has demonstrated that plant miRNAs exert cross-kingdom regulation on the target genes in animals. () is a valuable traditional Chinese medicine that has significant pharmacological activity against diseases of the central nervous system (CNS). Our previous studies have indicated that -specific miRNA plays a cross-kingdom regulatory role for the NF-B signaling pathway in mice. In this study, further bioinformatics analysis suggested that Gas-miR36-5p targets GSK-3β. Through western blot, RT-qPCR, and assessments of T-AOC, SOD, and MDA levels, Gas-miR36-5p demonstrated its neuroprotective effects in an AD cell model. Furthermore, Gas-miR36-5p was detected in the murine brain tissues. The results of the Morris water maze test and western blot analysis provided positive evidence for reversing the learning deficits and hyperphosphorylation of Tau in AD mice, elucidating significant neuroprotective effects in an AD model following RNA administration. Our research emphasizes Gas-miR36-5p as a novel -specific miRNA with neuroprotective properties in Alzheimer's disease by targeting GSK-3β. Consequently, our findings provide valuable insights into the cross-kingdom regulatory mechanisms underlying -specific miRNA, presenting a novel perspective for the treatment of Alzheimer's disease.

Citing Articles

Brain Glycogen-Its Metabolic Role in Neuronal Health and Neurological Disorders-An Extensive Narrative Review.

Beltran-Velasco A Metabolites. 2025; 15(2).

PMID: 39997753 PMC: 11857135. DOI: 10.3390/metabo15020128.


Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Cross-kingdom regulation of plant microRNAs: potential application in crop improvement and human disease therapeutics.

Shi L, Guo C, Fang M, Yang Y, Yin F, Shen Y Front Plant Sci. 2025; 15:1512047.

PMID: 39741676 PMC: 11685121. DOI: 10.3389/fpls.2024.1512047.


Identifying the quality markers and optimizing the processing of Gastrodiae rhizoma to treat brain diseases.

Fu Y, Xu Q, Zhang J, Kang C, Yang C, Guo L Front Pharmacol. 2024; 15:1396825.

PMID: 39568583 PMC: 11576197. DOI: 10.3389/fphar.2024.1396825.


Pan-Chloroplast Genomes Reveal the Accession-Specific Marker for f. .

Li J, Pan D, Wang J, Zeng X, Guo S Int J Mol Sci. 2024; 25(21).

PMID: 39519154 PMC: 11546827. DOI: 10.3390/ijms252111603.


References
1.
Filipowicz W, Jaskiewicz L, Kolb F, Pillai R . Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005; 15(3):331-41. DOI: 10.1016/j.sbi.2005.05.006. View

2.
Busche M, Konnerth A . Impairments of neural circuit function in Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci. 2016; 371(1700). PMC: 4938029. DOI: 10.1098/rstb.2015.0429. View

3.
Martin L, Latypova X, Wilson C, Magnaudeix A, Perrin M, Yardin C . Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2012; 12(1):289-309. DOI: 10.1016/j.arr.2012.06.003. View

4.
Kou X, Chen D, Chen N . The Regulation of microRNAs in Alzheimer's Disease. Front Neurol. 2020; 11:288. PMC: 7180504. DOI: 10.3389/fneur.2020.00288. View

5.
Avila J, Hernandez F . GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother. 2007; 7(11):1527-33. DOI: 10.1586/14737175.7.11.1527. View